FUTURESStock Futures Rise as Irma Weakens to Tropical Storm and North Korea Is QuietBy Kinsey GrantSep 11, 2017 8:43 AM EDT
STOCKSWhat Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016By Adam FeuersteinDec 22, 2016 11:20 AM EST
MARKETSPeregrine Pharmaceuticals (PPHM) Weak On High Volume TodayBy TheStreet WireJun 8, 2015 10:07 AM EDT
MARKETSPeregrine Pharmaceuticals (PPHM) Stock Gains on Revenue BeatBy Tony OwusuMar 12, 2015 5:00 PM EDT
MARKETSPeregrine Pharmaceuticals (PPHM) Highlighted As Weak On High VolumeBy Marissa GoodbodyMar 9, 2015 10:01 AM EDT
INVESTINGSarepta Soars After Announcing Publication of Ebola Drug Candidate DataBy The Fly StaffOct 17, 2014 10:47 AM EDT
INVESTINGEbola Linked Names Rise Again Amid Broader Market Sell-OffBy The Fly StaffOct 15, 2014 11:54 AM EDT
STOCKSBiotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech EventsBy Adam FeuersteinJul 14, 2014 9:30 AM EDT
STOCKSBiotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, MerrimackBy Adam FeuersteinMay 9, 2014 6:00 AM EDT
MARKETSPeregrine Pharmaceuticals (PPHM) Marked As A Dead Cat Bounce StockBy David M. AferiatMar 10, 2014 9:45 AM EDT
STOCKSBiotech Stock Mailbag: Exact Sciences, Rexahn, Advaxis, PeregrineBy Adam FeuersteinMar 7, 2014 10:49 AM EST
OPINIONConsider Buy Rated Stocks Under Five Bucks as Stocking StuffersBy Richard SuttmeierDec 23, 2013 10:28 AM EST
STOCKSFour Charts Tear Apart Peregrine Pharma's Quarterly Spin JobBy Adam FeuersteinSep 10, 2013 4:00 PM EDT
STOCKSPeregrine Pharma Is Wasting Money On A Placebo Cancer DrugBy Adam FeuersteinFeb 13, 2013 9:44 AM EST
STOCKSBiotech Stock Mailbag: Peregrine, Arena, Dendreon, NPS PharmaBy Adam FeuersteinJan 18, 2013 8:18 AM EST
STOCKSPeregrine Shows Desperation in Dusting Off Ancient Brain Tumor DrugBy Adam FeuersteinDec 5, 2012 4:25 PM EST
STOCKSYour Vote Counts: Who Is the Worst Biotech CEO of 2012?By Adam FeuersteinDec 4, 2012 8:30 AM EST
